Description
What is the Synedica Semaglutide® Injection Pen Kit?
The Synedica Semaglutide® Injection Pen Kit is a clinically advanced medical treatment designed to support weight loss. It contains semaglutide, widely known as Ozempic, a GLP-1 receptor agonist that mimics the natural hormone GLP-1. This hormone signals fullness to the brain, helping reduce appetite, cravings, and overall food intake.
For most new users, a single kit typically provides up to 12 weeks of treatment depending on dosage.
What’s Included in the 1mg Kit?
- 2 × Synedica Semaglutide pens (each containing 4mg)
- 12 × disposable 32G 4mm needles
- 1 × instruction booklet
Each pen can deliver:
- 4 full doses of 1mg, or
- maller adjustable doses: 0.25mg, 0.5mg, 0.75mg, or 1mg, based on the prescribed schedule.
Recommended Dosage Schedule (Typical Medical Guidance)
- Weeks 1–4: 0.25mg once weekly
- Weeks 5–8: 0.5mg once weekly
- After Week 8: May increase to 0.75mg or 1mg weekly, depending on your doctor’s advice
Key Benefits
- Helps reduce appetite and daily food cravings
- Supports steady and sustainable fat loss
- Makes smaller meals feel more satisfying
- Helps avoid extreme hunger associated with traditional dieting
- Possible Side Effects
Common mild–moderate side effects may include:
- Nausea
- Jaw discomfort
- Low mood or fatigue
- A complete list of side effects and safety information is included in the patient information booklet.
Cost & Availability
- Typical cost: ~€300 per kit (approx. 12-week supply) in private pharmacies
- May be covered under some employer health insurance plans
- In Germany, may be available to eligible patients through GKV (public insurance)
- Prescription only in Germany and most EU regions
Synedica vs Other GLP-1 Medications
Semaglutide
First-line GLP-1 treatment
- Targets 1 receptor (GLP-1)
- Widely used for appetite suppression and weight control
Tirzepatide
- Second-line option if semaglutide becomes less effective
- Dual-agonist: targets 2 receptors (GLP-1 & GIP)
- More potent at lower doses
Retatrutide
- Latest triple-agonist therapy
- Targets 3 receptors (GLP-1, GIP, and glucagon)
- Typically considered for patients who develop tolerance to tirzepatide







